Apogee Therapeutics moved to accelerate its late-stage atopic dermatitis program after securing up to $1.3 billion in non-dilutive funding from Blackstone Life Sciences. The capital is earmarked to fund development of zumilokibart (zumi), a long-acting anti–IL-13 antibody showing positive Phase 2 results for moderate-to-severe patients. The company disclosed interim part B data from the Apex trial and signaled plans to advance the program into Phase 3, subject to regulatory discussions. Apogee is also positioning zumilokibart as a potential front-line option in adult AD, aiming for broader differentiation in a crowded biologics landscape. Blackstone’s financing structure ties directly to the clinical and commercialization timeline for the asset, reducing dilution risk as Apogee scales operations for a pivotal readout. The deal arrives as payers and competitors increasingly scrutinize durability, dosing convenience, and safety profiles for anti–IL-13 and adjacent mechanisms. Separately, Apogee disclosed a related financing beat alongside its Phase 2 readouts, reinforcing momentum heading into the next clinical step.